CME
stockKey statsas of May 22
- Open
- $289.10
- -0.07%
- Close
- $291.23
- +0.67%
- Current
- $291.23
- Prev close
- $289.29
- Today
- 1.44M
- 3-mo avg
- 2.36M
Stock health
A read across the data this app already carries: fundamentals, recent price and growth trajectory, and leadership stability. Industry context is not yet folded in.
For fun and reading at a glance. Not investment advice and not a buy or sell signal.
Overall, CME reads as mixed.
- Fundamentals Fair across the nine graded ratios
- Trajectory Climbing trailing-year price trend + revenue / earnings growth
- Leadership — leadership sync has not reached this stock yet
Fundamentalssynced from SEC 1h ago
Across the nine graded ratios (FY2025 figures against the latest price), CME’s fundamentals read as fair overall.
At 26x, investors are paying up; a fair amount of future growth is already in the price.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
A 1.7% yield is modest: a small income on top of whatever the share price does.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 62.5% margin is strong; the company keeps a healthy slice of every revenue dollar.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 14.2% return on equity is respectable, in the normal range.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 2.1% return on assets is reasonable for a company of this kind.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 5.91, the company leans heavily on borrowing, which adds risk if results weaken.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 1.03, short-term assets cover short-term bills with a little room to spare.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 6.4% from the prior year: steady, modest expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income grew 15.5% from the prior year: strong profit expansion.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 1h ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $4.7B | $5.0B | $5.6B | $6.1B | $6.5B |
| Net income | $2.6B | $2.7B | $3.2B | $3.5B | $4.1B |
| Diluted EPS | $7.29 | $7.40 | $8.86 | $9.67 | $11.16 |
| Dividend / share | $5.90 | $8.50 | $9.65 | $10.40 | $5.00 |
| Total assets | $196.8B | $174.2B | $129.7B | $137.4B | $198.4B |
| Total liabilities | $169.4B | $147.3B | $103.0B | $111.0B | $169.7B |
| Shareholder equity | $27.4B | $26.9B | $26.7B | $26.5B | $28.7B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B | $1.6B | $1.5B | $1.6B | $1.7B | $1.5B | $1.6B | $1.9B |
| Net income | $883.2M | $912.8M | $874.6M | $956.2M | $1.0B | $908.0M | $1.2B | $1.2B |
| Diluted EPS | $2.42 | $2.50 | $2.40 | $2.62 | $2.81 | $2.49 | $3.24 | $3.18 |
| Dividend / share | $1.15 | $1.15 | $6.95 | $1.25 | $1.25 | $1.25 | $1.25 | $7.45 |
Leadership
Notable recent eventspast year
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Dividendssynced from Yahoo 2h ago
- 2025 total
- $5.00
- 2026 so far
- $7.451 payment
- 2026 projected
- $29.80+496.0% vs 2025
Projection scales CME’s declared payments so far this year up to the inferred cadence, then compares to last year’s total. Between payouts it is an estimate, not a guarantee.
Payment history
- Mar 10 $7.45
- Dec 12, 2025 $1.25
- Sep 9, 2025 $1.25
- Jun 9, 2025 $1.25
- Mar 7, 2025 $1.25
- Dec 27, 2024 $5.80
- Dec 9, 2024 $1.15
- Sep 9, 2024 $1.15
- Jun 7, 2024 $1.15
- Mar 7, 2024 $1.15
- Dec 27, 2023 $5.25
- Dec 7, 2023 $1.10
- Sep 7, 2023 $1.10
- Jun 8, 2023 $1.10
- Mar 9, 2023 $1.10
- Dec 27, 2022 $4.50
- Dec 8, 2022 $1.00
- Sep 8, 2022 $1.00
- Jun 9, 2022 $1.00
- Mar 9, 2022 $1.00
- Dec 27, 2021 $3.25
- Dec 9, 2021 $0.90
- Sep 9, 2021 $0.90
- Jun 9, 2021 $0.90
Recent SEC filingssynced from SEC 1h ago
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report